You are here

Home › RSV: US FDA approves Pfizer's RSV vaccine for older adults at increased risk › RSV: US FDA approves Pfizer's RSV vaccine for older adults at increased risk

RSV: US FDA approves Pfizer's RSV vaccine for older adults at increased risk

Primary tabs

RSV: US FDA approves Pfizer's RSV vaccine for older adults at increased risk

Wed, 2024-10-23 09:48 — mike kraft
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease. Reuters Reuters
 
In June, the U.S. CDC narrowed its recommendation for the use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.
 
The CDC has now recommended the use of RSV vaccines in adults aged 75 years or older, and those aged 60-74 who are at increased risk for severe RSV disease.
...
Country / Region Tags: 
Global
United States
General Topic Tags: 
RSV
Demographics
Disease Prevention
Government
Health
Public Health
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
Global Health
Medical - global
Vaccines
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.486 seconds.